Brief

A recent review paper published on arXiv details the computational methods and challenges associated with using cell-free DNA (cfDNA) for multi-cancer early detection (MCED). The paper, covering research from 2022 to 2025, examines how fragmentomics and epigenetic features are analyzed to identify cancer in its early stages. It discusses various approaches, including statistical, machine learning, and deep learning models, evaluating their biological interpretability, validation, and clinical readiness. The review highlights that multimodal ensemble methods show the most promise for clinical integration, but emphasizes the need for standardized evaluation protocols to facilitate future comparisons and advancements. AI